The claim appeared on Facebook and elsewhere on X, including in a post by Stella Immanuel, a Houston-based physician born in ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Arvinas shares plunged 45% after its Pfizer-partnered breast cancer drug, vepdegestrant, failed to delay cancer progression for all patients. The drug only met its goal for a subset of patients with a ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...